

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

CANCELLATION OF THE REPURCHASED H SHARES

Reference is made to the circular (the “**Circular**”) dated 18 November 2023 and the announcements dated 30 October 2023 and 19 December 2023 of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) in relation to the grant of general mandate to the Board to repurchase H shares of the Company (the “**H Share Repurchase Mandate**”) and the next day disclosure return dated 7 January 2024, 10 January 2024, 11 January 2024, 16 January 2024, 17 January 2024, 18 January 2024, 22 January 2024, 23 January 2024, 26 January 2024, 29 January 2024, 31 January 2024, 5 February 2024, 24 April 2024 and 25 April 2024. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at 27 June 2024, the Company made a total repurchase of 2,778,800 H Shares of the Company, accounting for 0.30% of the total issued share capital and 0.90% of the total number of issued H Shares of the Company on 27 June 2024. The highest purchase price was HK\$26.15 per share and the lowest purchase price was HK\$23.05 per share. Total amount of funds used was HK\$68,157,390.00 (excluding transaction costs). The share repurchase mentioned above complies with the H Share Repurchase Mandate.

On 28 June 2024, the Repurchased H Shares were cancelled and the registered capital of the Company will be reduced by RMB2,778,800.00. The Company will go through relevant registration formalities of the change as soon as possible.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
28 June 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*